All News

PSA2L.jpg

Combination treatments in Psoriatic Arthritis

Antoni Chan, MD, PhD

Despite the advances in the treatment of PsA with biologic (bDMARD) and targeted synthetic (tsDMARD), less than half of patients with this condition achieved remission or low disease activity. Combination DMARD treatment is often used in order to achieve remission or minimal disease activity. The standard practice is to use a conventional synthetic (csDMARD) with a bDMARD. The use of the combination of bDMARD with a tsDMARD such as a JAKi or TYK2i is a new order in the treatment of PsA.

Read Article
PMR,flag

Secukinumab promise in PMR is real

David Liew, FRACP

Choice is not just good, it is often necessary, and secukinumab promises just that in both PMR and GCA.

Read Article
GCA,woman

Secukinumab Use in Refractory Giant Cell Arteritis

Jack Cush, MD

In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab.

Read Article
Biologic.choice.MD_.jpeg (keep)

Biologics in Pregnancy Patients With Autoimmune Disease

Jack Cush, MD

A large cohort, claims data study shows that among pregnant women receiving biologic therapies for autoimmune conditions, 72% continued their biologics pregnancy, more so among inflammatory bowel disease (IBD) patients than those with rheumatoid arthritis (RA), psoriasis (PsO) or psoriatic arthri

Read Article
RheumNow Podcast square

Rheumatology: Believe It or Not (4/25/2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Should we believe the reviews and metanalyses?

Read Article
guidelines.recommendations.jpg

2025 BSR Guideline for Treatment of Axial Spondyloarthritis

Jack Cush, MD

The British Society of Rheumatology has published its 2025 Guidelines for the Treatment of Axial Spondyloarthritis (axSpA); addressing axial and extra-musculoskeletal manifestations including acute anterior uveitis, psoriasis and IBD.

Read Article
RheumNow Podcast square

Osteoarthritis Risky Business (4.18.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and Journal reports from this week on RheumNow.com.  Osteoarthritis patients have unique risks and synovial fluid WBC numbers can tell you when to worry about septic arthritis in gout and pseudogout patients.

Read Article
❓️How effective and safe is it to combine bDMARDs and tsDMARDS (i.e. TNFi/ IL17i + JAKi/TYKi) in #psoriatic_arthritis? 🅰️ Reassuring data from a case-series study presented by Andre Lucas Ribeiro #EULAR2025 OP0090 @RheumNow #Strategy https://t.co/W8fuzSgxbJ

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
Ph 2 RCT Sonelokimab (IL-17A- & IL-17F-inhibiting Nanobody) 24wks 207 pts SON 120 MDA 51% vs. 45% ADA Subgroups: female 52%, weight ≥100kg 53%, ≥3% BSA 55% Composite ACR70/PASI100 SON 120 48% vs. 19% ADA No new safety signal Ph 3 on the way 2 doses SON 60 &120 #OP0096 https://t.co/w5QtpKbi1W

Links:

Aurelie Najm AurelieRheumo ( View Tweet)

IL-17 inhibition for PMR? In the secukinumab ph2 in GCA (TitAIN), patients with PMR did really well, seemingly outperforming steroid taper in the placebo arm. Real promise, will be great to see how the ph3 in PMR (REPLENISH) goes OP0062 #EULAR2025 @RheumNow https://t.co/cisA0GiUx1

Links:

David Liew drdavidliew ( View Tweet)
Xeligekimab in AS: -IL-17A blocker -Phase 3 study on Chinese pts showed sustained efficacy until week 48. -Significant improvement on DAI measures as well. -Fully humanized IgG4 mab may last longer in system and possible less ADAs. Abstract #OP0102 #EULAR2025 @RheumNow https://t.co/vyNHZ9ssFt

Links:

Adela Castro AdelaCastro222 ( View Tweet)

📊 POS0574 @rheumnow #EULAR2025 Real-world data from SERENA shows sustained 5-year effectiveness of secukinumab in PsA. ✔️ 57% had no tender/swollen joints at Year 5 ✔️ PASI90 in ~48% ✔️ Stable low TJC, SJC & PtGA Durability confirmed even in prior biologic users. https://t.co/eNpboTRRu3

Links:

Jiha Lee JihaRheum ( View Tweet)
Early PsA? Treat fast, treat hard. The STAMP RCT showed that early secukinumab + MTX led to faster ACR50 and PASI90 responses vs standard care in a T2T strategy. By 12 months, outcomes were similar, but early SEC needed fewer escalations. Abstract#OP0092 @RheumNow #EULAR2025 https://t.co/cAZTc9eN16

Links:

Jiha Lee JihaRheum ( View Tweet)
Case series of 22 PsA pts treats w/ combination bioDMARDs & JAKi,TYK2i or APR IL17i + JAKi 10.5 PY = 1 mild infectious stomatitis IL23i + JAKi 3.7 PY = no AE IL-17i + TYK2i 8.5 PY = 2 mild upper respiratory infections IL-23i + TYK2i 8.3 PY = 2 mild URIs, 1 folliculitis TNFi + https://t.co/Qg9HIwuslJ

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Can IL-17F signalling be modulated by treatment with TNFi? In PsA pts non responders to previous TNFi, there was increased expression of IL17F-related gene signature. Suggesting a potential mechanism for the consistent level of clinical response observed with BKZ. Abstract https://t.co/D6fvp18UTz

Links:

Adela Castro AdelaCastro222 ( View Tweet)
Early intensive therapy in PsA. STAMP RCT in early PsA: •ACR50 at 3mo: 43% (early secukinumab) vs 22% (SoC) •MDA at 3mo: 48% vs 25% •PASI90 at 3mo: 60% vs 22% By 12months: outcomes similar, but early secukinumab led to faster control and fewer therapy escalations. https://t.co/TKa5z24NQX

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
STAMP RCT early SEC vs. SoC 120pts Retention 58% vs 30% ACR 20, 50, 70 and MDA: better outcome at Month 3 but no difference at Month 6 Dactylitis no difference Of note here SoC was a tight T2T strategy! @RheumNow #OP0092 #EULAR2025 https://t.co/8zHs5CRFV5

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Swiss Registry study of PsA outcomes when started on either TNFi (N 503) or IL-17i (n 341), latter w/ more severe PSO. IL-17i durability superior to TNFi (median 828 vs 445 d, P<.001), w/ less D/C in women (HR 0.57); but ACR 20 (14 v 33%) & ACR50 (7 v 24%) favored TNFi use https://t.co/R33bwSeB3E
Dr. John Cush RheumNow ( View Tweet)
TriNetX EMR ulation study of CV risk w/ biologics in Psoriasis pts shows signifcant reduced CV events in PsO pts taking r\TNFi (HR 0.886), IL-17i (HR 0.724), IL-23i (HR 0.739); not anti-IL-12/23 (HR 0.915); Risk reduction applied to all subgroups (age, comorbidity, Wt) https://t.co/67c5yqK80h
Dr. John Cush RheumNow ( View Tweet)
IL-17 inhibitors increase risk of IBD. TriNetX database study of PsO & AS pts starting IL-17i vs apremilast. 13,216 matched pts per group, 142 developed IBD w/ IL-17i vs. 60 with apremilast (aHR = 2.50, 95% CI: 1.85–3.39). https://t.co/sSPqKsfbZ4 https://t.co/YCqDUzX9xq

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×